Page 21 - Read Online

van der Ent et al. J Transl Genet Genom 2018;2:10. I https://doi.org/10.20517/jtgg.2018.09 Page 7 of 12

DECLARATIONS
Authors’ contributions
Literature research and manuscript writing: van der Ent W, Sand LGL, Hogendoorn PCW
Manuscript editing: van der Ent W, Hogendoorn PCW

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumours of soft tissue and bone, 4th ed. Lyon, France:
IARC Press; 2013.
2. Ewing J. Diffuse endothelioma of bone. Proc N Y Path 1921;21:17-24.
3. Lizard-Nacol S, Lizard G, Justrabo E, Turc-Carel C. Immunologic characterization of Ewing’s sarcoma using mesenchymal and neural
markers. Am J Pathol 1989;135:847-55.
4. Maurer HM. Solid tumors in children. N Engl J Med 1978;299:1345-8.
5. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing’s sarcoma. Oncogene 2010;29:4504-16.
6. Geens L, Robays JV, Geert V, der Speeten KV. An unusual location of extraosseous Ewing’s sarcoma. Case Rep Oncol 2013;6:293-302.
7. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology, 6th ed. Philadelphia, United States: Wolters Kluwer Health/Lippincott
Williams & Wilkins; 2011.
8. Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, Versari M, Setola E, Briccoli A, Barbieri E. Therapy and survival after
recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to
1997. Ann Oncol 2003;14:1654-9.
9. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley
KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG. High-dose melphalan, etoposide, total-body irradiation, and autologous
stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812-20.
10. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H. Ewing’s sarcoma family of tumors: current management.
Oncologist 2006;11:503-19.
11. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol 2010;11:184-92.
12. Hamilton SN, Carlson R, Hasan H, Rassekh SR, Goddard K. Long-term outcomes and complications in pediatric Ewing sarcoma. Am J
Clin Oncol 2017;40:423-8.
13. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Fröhlich B, Winkelmann W, Zoubek A, Jürgens H. Primary
metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing
Sarcoma Studies. Ann Oncol 1998;9:275-81.
14. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS,
Moore S, Rausen AR, Vietti TJ, Grier HE. Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation
of combination ifosfamide and etoposide--a Children’s Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-6.
15. Drabko K, Raciborska A, Bilska K, Styczynski J, Ussowicz M, Choma M, Wojcik B, Zaucha-Prazmo A, Gorczynska E, Skoczen S,
Wozniak W, Chybicka A, Wysocki M, Gozdzik J, Kowalczyk J. Consolidation of first-line therapy with busulphan and melphalan, and
autologous stem cell rescue in children with Ewing’s sarcoma. Bone Marrow Transplant 2012;47:1530-4.
16. Ladenstein R, Pötschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I,